Angiotensin Receptor Blockers for the Treatment of Hypertension in Children

Abstract

Get full access to this article

View all access options for this article.

References

Mitsnefes MM Hypertension in children and adolescents. Pediatr Clin North Am. 2006;53:493-512.

Sorof J. , Daniels S. Obesity hypertension in children: a problem of epidemic proportions. Hypertension. 2002;40: 441-447.

Thompson DR , Obarzanek E. , Franko DL , et al. Childhood overweight and cardiovascular disease risk factors: the National Heart, Lung, and Blood Institute Growth and Health Study. J Pediatr. 2007;150(1):18-25.

Kim MS Pediatric hypertension. Circulation. 2005;111:e97.

National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004;114:555-576.

Flynn JT Evaluation and management of hypertension in childhood. Prog Pediatr Cardiol. 2001;12:177-188.

Gruskin AB Factors affecting blood pressure. In: Drukker A , Gruskin AB , eds. Pediatric Nephrology: Pediatric and Adolescent Medicine. 3rd ed. Basel, Switzerland: Karger ; 1995:1097.

Portman RJ , McNiece KL , Swinford RD , Braun MC , Samuels JA Pediatric hypertension: diagnosis, evaluation, management, and treatment for the primary care physician. Curr Probl Pediatr Adolesc Health Care. 2005;35: 262-294.

Nguyen G. , Delarue F. , Burcklé C. , Bouzhir L. , Giller T. , Sraer JD Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest. 2002;109:1417-1427.

10.

Israili ZH Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension . J Hum Hypertens. 2000;14(Suppl 1):S73-S86.

11.

Dahlof B. , Devereux RB , Kjeldsen SE , et al; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003.

12.

Malmqvist K. , Kahan T. , Edner M. , et al. Regression of left ventricular hypertrophy in human hypertension with irbesartan. J Hypertens. 2001;19:1167-1176.

13.

Dickstein K. , Kjekshus J. ; OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomized trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet. 2002;360: 752-760.

14.

Pfeffer MA , McMurray JJ , Velazquez EJ , et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893-1906.

15.

Pfeffer MA , Swedberg K. , Granger CB , et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003;362:759-766.

16.

Cohn JN , Tognoni G. ; Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667-1675.

17.

Moffett BS , Chang AC Future pharmacologic agents for treatment of heart failure in children. Pediatr Cardiol. 2006;27:533-551.

18.

Lewis EJ , Hunsicker LG , Clarke WR , et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860.

19.

Parving HH , Lehnert H. , Brochner-Mortensen J. , et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870-878.

20.

Brenner BM , Cooper ME , de Zeeuw D. , et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med . 2001;345:861-869.

21.

Salcedo-Alejos M. , Banda-Espinoza F. , Rodriguez-Moran M. , Guerrero-Romero F. Irbesartan reduces creatinine clearance in type 1 diabetic children with renal hyperfunction: a randomized, double-blind placebo-controlled trial. Nephrol Dial Transplant. 2005;20:2120-2155.

22.

Ellis D. , Moritz ML , Vats A. , Janosky JE Antihypertensive and renoprotective efficacy and safety of losartan. A long-term study in children with renal disorders. Am J Hypertens. 2004;17:928-935.

23.

Hunt SA ; American College of Cardiology; American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol. 2005 ;46:e1-e82.

24.

Chobanian AV , Bakris GL , Black HR , et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560-2572.

25.

Flynn JT , Meyers KE , Neto JP , et al. Efficacy and safety of the angiotensin receptor blocker valsartan in children with hypertension aged 1 to 5 years. Hypertension . 2008;52:222-228.

26.

Yamagishi S. , Nakamura K. Telmisartan, its potential therapeutic implications in cardiometabolic disorders. Recent Patents Cardiovasc Drug Discov. 2006;1:79-83.

27.

Maillard MP , Perregaux C. , Centeno C. , et al. In vitro and in vivo characterization of the activity of telmisartan: an insurmountable angiotensin II receptor antagonist. J Pharmacol Exp Ther. 2002;302:1089-1095.

28.

Weinberg AJ , Zappe DH , Ashton M. , Weinberg MS Safety and tolerability of high-dose angiotensin receptor blocker therapy in patients with chronic kidney disease: a pilot study. Am J Nephrol. 2004;24:340-345.

29.

Weinberg AJ , Zappe DH , Ramadugu R. , Weinberg MS Long-term safety of high-dose angiotensin receptor blockers therapy in hypertensive patients with chronic kidney disease . J Hypertens Suppl. 2006;24:S95-S99.

30.

Aranda O. , Segura J. , Ruilope LM , et al. Long-term renoprotective effects of standard versus high doses of telmisartan in hypertensive nondiabetic nephropathies. Am J Kidney Dis. 2005;46:1074-1079.

31.

Simonetti GD , von Vigier RO , Konrad M. , Rizzi M. , Fossali E. , Bianchetti MG Candesartan cilexetil in children with hypertension or proteinuria: preliminary data. Pediatr Nephrol. 2006;21:1480-1482.

32.

Bos-Thompson MA , Hillaire-Buys D. , Muller F. , et al. Fetal toxic effects of angiotensin II receptor antagonists: case report and follow-up after birth. Ann Pharmacother. 2005;39:157-161.

33.

Shahinfar S. , Cano F. , Soffer BA , et al. A double-blind, dose-response study of losartan in hypertensive children. Am J Hypertens. 2005;18(2Pt1):183-190.

34.

Wells T. , Blumer J. , Litwin M. , et al. Safety and effectiveness of valsartan (VAL) in hypertensive children ages 6-16 years. J Clin Hypertens ( Greenwich). 2007;9(5 SupplA):A79-A80.

35.

Franks AM , O’Brien CE , Stowe CD , Wells TG , Gardner SF Candesartan cilexetil effectively reduces blood pressure in hypertensive children . Ann Pharmacother. 2008;42: 1388-1395.

36.

Chandar J. , Abitbol C. , Montané B. , Zilleruelo G. Angiotensin blockade as sole treatment for proteinuric kidney disease in children . Nephrol Dial Transplant. 2007;22: 1332-1337.

37.

Coppo R. , Amore A. , Peruzzi L. , Mancuso D. , Camilla R. Angiotensin antagonists and fish oil for treating IgA nephropathy. Contrib Nephrol. 2007;157:27-36.

38.

Grenier MA , Fioravanti J. , Truesdell SC , Mendelsohn AM , Vermilion RP , Lipshultz SE Angiotensin-converting enzyme inhibitor therapy for ventricular dysfunction in infants, children and adolescents: a review. Prog Pediatr Cardiol. 2000;12:91-111.

39.

Momma K. ACE inhibitors in pediatric patients with heart failure. Paediatr Drugs. 2006;8:55-69.

40.

Lipshultz SE Ventricular dysfunction clinical research in infants, children and adolescents. Prog Pediatr Cardiol. 2000;12:1-28.

41.

Baum MA , Harris HW Jr , Burrows PE , Schofield DE , Somers MJ Renovascular hypertension in Marfan syndrome. Pediatr Nephrol . 1997;11:499-501.

42.

Mizuguchi T. , Collod-Beroud G. , Akiyama T. , et al. Heterozygous TGFBR2 mutations in Marfan syndrome. Nat Genet. 2004;36:855-860.

43.

Neptune ER , Frischmeyer PA , Arking DE , et al. Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat Genet. 2003;33:407-411.

44.

Pyeritz RE A small molecule for a large disease. N Engl J Med. 2008;358:2829-2831.

45.

Brooke BS , Habashi JP , Judge DP , Patel N. , Loeys B. , Dietz HC 3rd. Angiotensin II blockade and aortic-root dilation in Marfan’s syndrome . N Engl J Med. 2008;358: 2787-2795.

46.

Matt P. , Habashi J. , Carrel T. , Cameron DE , Van Eyk JE , Dietz HC Recent advances in understanding Marfan syndrome: should we now treat surgical patients with losartan? J Thorac Cardiovasc Surg. 2008;135:389-394.

47.

Luma GB , Spiotta RT Hypertension in children and adolescents. Am Fam Physician . 2006;73:1558-1568.